WO2005023176A3 - Delivery of physiologixal agents with in-situ gels comprising anionic polysaccharides - Google Patents
Delivery of physiologixal agents with in-situ gels comprising anionic polysaccharides Download PDFInfo
- Publication number
- WO2005023176A3 WO2005023176A3 PCT/US2004/016146 US2004016146W WO2005023176A3 WO 2005023176 A3 WO2005023176 A3 WO 2005023176A3 US 2004016146 W US2004016146 W US 2004016146W WO 2005023176 A3 WO2005023176 A3 WO 2005023176A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- delivery
- agents
- anionic polysaccharides
- physiologixal
- tissues
- Prior art date
Links
- 238000011065 in-situ storage Methods 0.000 title abstract 3
- 229920001586 anionic polysaccharide Polymers 0.000 title abstract 2
- 150000004836 anionic polysaccharides Chemical class 0.000 title abstract 2
- 239000003795 chemical substances by application Substances 0.000 title 1
- 239000000499 gel Substances 0.000 title 1
- 239000013543 active substance Substances 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 210000001124 body fluid Anatomy 0.000 abstract 1
- 239000010839 body fluid Substances 0.000 abstract 1
- 239000003349 gelling agent Substances 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 abstract 1
- 229920001277 pectin Polymers 0.000 abstract 1
- 239000001814 pectin Substances 0.000 abstract 1
- 235000010987 pectin Nutrition 0.000 abstract 1
- 239000000843 powder Substances 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
- 238000013268 sustained release Methods 0.000 abstract 1
- 239000012730 sustained-release form Substances 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55583—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Abstract
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2537290A CA2537290C (en) | 2003-08-29 | 2004-05-24 | Delivery of physiological agents with in-situ gels comprising anionic polysaccharides |
AU2004270101A AU2004270101A1 (en) | 2003-08-29 | 2004-05-24 | Delivery of physiologixal agents with in-situ gels comprising anionic polysaccharides |
JP2006524618A JP4765020B2 (en) | 2003-08-29 | 2004-05-24 | Physiological drug delivery in situ gels containing anionic polysaccharides |
EA200600484A EA010351B1 (en) | 2003-08-29 | 2004-05-24 | Delivery of physiological agents withgels comprising anionic polysaccharides |
EP04753044A EP1663111A4 (en) | 2003-08-29 | 2004-05-24 | Delivery of physiologixal agents with in-situ gels comprising anionic polysaccharides |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/652,622 US7494669B2 (en) | 2001-02-28 | 2003-08-29 | Delivery of physiological agents with in-situ gels comprising anionic polysaccharides |
US10/652,622 | 2003-08-29 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2005023176A2 WO2005023176A2 (en) | 2005-03-17 |
WO2005023176A3 true WO2005023176A3 (en) | 2006-06-15 |
Family
ID=34273408
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2004/016146 WO2005023176A2 (en) | 2003-08-29 | 2004-05-24 | Delivery of physiologixal agents with in-situ gels comprising anionic polysaccharides |
Country Status (9)
Country | Link |
---|---|
US (1) | US7494669B2 (en) |
EP (1) | EP1663111A4 (en) |
JP (1) | JP4765020B2 (en) |
KR (1) | KR20060127841A (en) |
CN (1) | CN1874679A (en) |
AU (1) | AU2004270101A1 (en) |
CA (1) | CA2537290C (en) |
EA (1) | EA010351B1 (en) |
WO (1) | WO2005023176A2 (en) |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7022683B1 (en) * | 1998-05-13 | 2006-04-04 | Carrington Laboratories, Inc. | Pharmacological compositions comprising pectins having high molecular weights and low degrees of methoxylation |
US20050113730A1 (en) * | 2003-11-24 | 2005-05-26 | Sca Hygiene Products Ab | Absorbent Article Containing A Skin Care Product |
AR048709A1 (en) * | 2004-04-26 | 2006-05-17 | Cp Kelco Aps | DERMOPROTECTOR COMPOSITION TO CONTROL THE ALKALINITY AND USE OF IT |
US20060106117A1 (en) * | 2004-11-12 | 2006-05-18 | Kimberly-Clark Worldwide, Inc. | Compound and method for prevention and/or treatment of vaginal infections |
US20060223765A1 (en) * | 2005-03-30 | 2006-10-05 | Kimberly-Clark Worldwide, Inc. | Method for inhibiting and/or treating vaginal infection |
US7786176B2 (en) | 2005-07-29 | 2010-08-31 | Kimberly-Clark Worldwide, Inc. | Vaginal treatment composition containing xylitol |
CA2633655A1 (en) * | 2005-12-19 | 2007-07-05 | Comentis, Inc. | Topical mecamylamine formulations for ocular administration and uses therof |
KR20100014509A (en) * | 2007-03-13 | 2010-02-10 | 바이오라인알엑스 리미티드 | A method of promoting tissue repair |
CN101720226B (en) * | 2007-05-11 | 2013-01-30 | 芦荟研究实验室公司 | Aloe preparation for skin enhancement |
PT2268142T (en) | 2007-11-27 | 2017-06-02 | Algipharma As | Use of alginated oligomers in combating biofilms |
JP2009209086A (en) * | 2008-03-04 | 2009-09-17 | Masami Moriyama | Mucous membrane administration-type vaccine |
US7833829B2 (en) * | 2008-10-28 | 2010-11-16 | Honeywell International Inc. | MEMS devices and methods of assembling micro electromechanical systems (MEMS) |
GB0909557D0 (en) | 2009-06-03 | 2009-07-15 | Algipharma Ipr As | Anti-microbial alginate oligomers |
GB0909529D0 (en) | 2009-06-03 | 2009-07-15 | Algipharma Ipr As | Alginate oligomers for the inhibition of microbial adherence to surfaces |
ES2444541T3 (en) | 2009-06-03 | 2014-02-25 | Algipharma As | Alginate oligomers to use to overcome drug multiresistance in bacteria |
JP2011057605A (en) * | 2009-09-09 | 2011-03-24 | Masami Moriyama | Vaccine to be applied to mucous membrane |
CN101703490B (en) * | 2009-11-13 | 2013-08-07 | 杭州师范大学 | Polysaccharide/inorganic nanoparticles hybrid micron-nano medicine-carrying capsule |
US8852645B2 (en) | 2009-11-19 | 2014-10-07 | The Board Of Trustees Of The University Of Illinois | Self-assembled toroidal-spiral particles and manufacture and uses thereof |
US9439958B2 (en) * | 2009-12-23 | 2016-09-13 | Arizona Board Of Regents Acting For And On Behalf Of Arizona State University | Stabilized virus like particles having enhanced mucosal immunogenicity |
JP5996837B2 (en) * | 2010-05-28 | 2016-09-21 | 小林製薬株式会社 | Influenza virus infection inhibitor |
FR2960775A1 (en) * | 2010-06-07 | 2011-12-09 | Ethypharm Sa | MICROGRANULES RESISTANT TO MISMATCH |
ITVR20100140A1 (en) * | 2010-07-13 | 2012-01-14 | Eurocoating S P A | COMPOSITE MATERIAL FORMED BY PECTIN AND CALCIUM PHOSPHATE AND METHOD FOR ITS REALIZATION |
SG10201507554RA (en) | 2010-09-13 | 2015-10-29 | Bev Rx Inc | Aqueous drug delivery system comprising off - flavor masking agent |
CA2833369C (en) * | 2011-04-18 | 2020-09-08 | Donald A. Harn | Vaccine delivery method |
GB2490516A (en) | 2011-05-03 | 2012-11-07 | Systagenix Wound Man Ip Co Bv | Polysaccharide mould for wound treatment |
GB201116010D0 (en) | 2011-09-15 | 2011-10-26 | Algipharma As | Use of alginate oligomers to enhance the effects of antifungal agents |
EP2782603A1 (en) | 2011-11-25 | 2014-10-01 | Danmarks Tekniske Universitet | Formulation of solid nano-sized particles in a gel-forming system |
CN102429862B (en) * | 2011-11-29 | 2013-05-01 | 江苏德达医药科技有限公司 | Sustained-release povidone iodine eye drops |
GB201322777D0 (en) | 2013-12-20 | 2014-02-05 | Algipharma As | Use of alginate oligomers as blood anticoagulants |
US20160158174A1 (en) * | 2014-12-09 | 2016-06-09 | Intercontinental Great Brands Llc | Enteric-Coated Functional Food Ingredients And Methods For Making The Enteric-Coated Functional Food Ingredients |
EP3034070A1 (en) * | 2014-12-18 | 2016-06-22 | Omya International AG | Method for the production of a pharmaceutical delivery system |
US20180008646A1 (en) * | 2015-01-30 | 2018-01-11 | Nissan Chemical Industries, Ltd. | Method for cultivating vascular smooth muscle cells |
KR101777910B1 (en) * | 2015-04-30 | 2017-09-13 | 주식회사 제네웰 | A composition for wound healing, method of producing the same and dressing using the same |
US11045578B2 (en) | 2015-06-24 | 2021-06-29 | Biovotec As | Tissue engineering scaffolds comprising particulate egg shell membrane |
US20180243397A1 (en) | 2015-08-28 | 2018-08-30 | Ron Cobb | Norovirus vaccine |
GB201517639D0 (en) | 2015-10-06 | 2015-11-18 | Algipharma As | Use of alginate oligomers to treat or prevent microbial overgrowth in the intestinal tract |
GB201519923D0 (en) | 2015-11-11 | 2015-12-23 | Biovotec Dac And Biovotec As | Dry biocompatible disintegrateable films for delivering particulate egg shell membrane to a wound |
WO2017151651A1 (en) * | 2016-02-29 | 2017-09-08 | Belmont University | Pharmaceutical in situ gelling compositions |
GB201618291D0 (en) | 2016-10-28 | 2016-12-14 | Bergen Teknologioverf�Ring As | Novel immunotherapeutic treatments for tumours |
US10912858B2 (en) * | 2017-05-01 | 2021-02-09 | The Brigham And Women's Hospital, Inc. | Pectin-carboxymethylcellulose mesothelial sealants and protectants |
EP3651588B1 (en) | 2017-07-11 | 2024-03-13 | Givaudan SA | Method for preparing a colour-stable preparation of a magnesium chlorophyllin alkali metal salt or alkali earth metal salt from natural sources of chlorophyll |
EP3694491A1 (en) | 2017-10-10 | 2020-08-19 | Capsugel Belgium NV | Gelling multiparticulates |
WO2019092608A1 (en) | 2017-11-08 | 2019-05-16 | Materias S.R.L. | In situ gelifying powder |
EP3556398A1 (en) | 2018-04-16 | 2019-10-23 | Croda Denmark A/S | Phytates for use as a biomolecules delivery or adsorption system |
GB201908639D0 (en) | 2019-06-17 | 2019-07-31 | Algipharma Ipr As | Use of alginate oligomers in the anticoagulation therapy of subjects at risk of blood clots which have an abnormally dense microstructure |
US11793230B2 (en) | 2019-12-09 | 2023-10-24 | Nicoventures Trading Limited | Oral products with improved binding of active ingredients |
US11872231B2 (en) | 2019-12-09 | 2024-01-16 | Nicoventures Trading Limited | Moist oral product comprising an active ingredient |
US11826462B2 (en) | 2019-12-09 | 2023-11-28 | Nicoventures Trading Limited | Oral product with sustained flavor release |
CN114146169B (en) * | 2021-12-28 | 2023-08-25 | 佛山市正典生物技术有限公司 | Carrier composition for chicken coccidium spray-drop immunization, using method and chicken coccidium spray-drop immunization composition |
WO2024004159A1 (en) * | 2022-06-30 | 2024-01-04 | Eps創薬株式会社 | Vaccine composition for sublingual administration |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4978528A (en) * | 1986-06-23 | 1990-12-18 | Bio Serae Laboratoires S.A. | Process for preventing degradation of an anti-bacterial composition |
Family Cites Families (157)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2629665A (en) * | 1951-10-31 | 1953-02-24 | James B Gordon | Dietetic food product and method of preparing the same |
US3622559A (en) | 1967-11-01 | 1971-11-23 | Sunkist Growers Inc | Method for producing pectins having high resistance to breakage and high capability for gelling in the presence of calcium |
US3946110A (en) * | 1974-05-30 | 1976-03-23 | Peter, Strong Research And Development Company, Inc. | Medicinal compositions and methods of preparing the same |
US3982003A (en) | 1974-09-04 | 1976-09-21 | Mars Limited | Gelling and thickening agents |
US4016351A (en) | 1976-02-04 | 1977-04-05 | Eschinasi Emile H | Pectic substances with varying methoxyl content and process therefor |
HU179474B (en) | 1978-02-24 | 1982-10-28 | Laszlo Gyarmati | Process for preparing solid oral pharmaceutical compositons with increased length of activity and with a regulated release of the active material |
US4305933A (en) | 1980-03-10 | 1981-12-15 | Wiczer Sol B | Thickened gelatinous edible alcoholic medicated carrier |
JPS607965B2 (en) * | 1980-08-07 | 1985-02-28 | 帝人株式会社 | Method for manufacturing powder for nasal mucosal administration |
US4497838A (en) | 1982-02-17 | 1985-02-05 | Tropicana Products, Inc. | Process for the production of useful products from orange peel |
US4735935A (en) | 1985-12-17 | 1988-04-05 | Carrington Laboratories, Inc. | Process for preparation of aloe products products, produced thereby and compositions thereof |
US4966892A (en) | 1982-05-07 | 1990-10-30 | Carrington Laboratories, Inc. | Processes for preparation of aloe products products produced thereby and compositions thereof |
US5106616A (en) | 1988-01-14 | 1992-04-21 | Carrington Laboratories, Inc. | Administration of acemannan |
US5308838A (en) | 1982-05-07 | 1994-05-03 | Carrington Laboratories, Inc. | Uses of aloe products |
US5118673A (en) | 1982-05-07 | 1992-06-02 | Carrington Laboratories, Inc. | Uses of aloe products |
US4917890A (en) | 1985-06-28 | 1990-04-17 | Carrington Laboratories, Inc. | Processes for preparation of aloe products, products produced thereby and compositions thereof |
US4851224A (en) | 1986-06-05 | 1989-07-25 | Carrington Laboratories, Inc. | Process for preparation of aloe products |
US5443830A (en) | 1982-05-07 | 1995-08-22 | Carrington Laboratories, Inc. | Drink containing mucilaginous polysaccharides and its preparation |
US5656587A (en) | 1982-09-24 | 1997-08-12 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Promotion of cell proliferation by use of transforming growth factor beta (TGF-β) |
US4500510A (en) | 1982-09-29 | 1985-02-19 | Aquarium Pharmaceuticals, Inc. | Damaged fish tissue treating method and composition containing Aloe vera extract |
JPS59163313A (en) | 1983-03-09 | 1984-09-14 | Teijin Ltd | Peptide hormone composition for nasal administration |
JPS60100516A (en) | 1983-11-04 | 1985-06-04 | Takeda Chem Ind Ltd | Preparation of sustained release microcapsule |
US5288498A (en) | 1985-05-01 | 1994-02-22 | University Of Utah Research Foundation | Compositions of oral nondissolvable matrixes for transmucosal administration of medicaments |
DE3583799D1 (en) | 1985-01-11 | 1991-09-19 | Abbott Lab Ltd | SOLID PREPARATION WITH SLOW RELEASE. |
US4957907A (en) | 1985-06-28 | 1990-09-18 | Carrington Laboratories Inc. | Process for preparation of aloe products |
US4959214A (en) | 1985-06-28 | 1990-09-25 | Carrington Laboratories Inc. | Processes for preparation of aloe products products produced thereby and compositions thereof |
EP0248051A1 (en) | 1985-11-29 | 1987-12-09 | FISONS plc | Pharmaceutical composition including sodium cromoglycate |
DE3601132A1 (en) | 1986-01-16 | 1987-07-23 | Christian Bannert | METHOD FOR TREATING THE MUCUS |
DE3601923A1 (en) | 1986-01-23 | 1987-07-30 | Behringwerke Ag | NASAL APPLICABLE MEDICINE, METHOD FOR THE PRODUCTION AND USE THEREOF |
US5552528A (en) | 1986-03-03 | 1996-09-03 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bovine b-endothelial cell growth factor |
US4725438A (en) | 1986-05-29 | 1988-02-16 | Leazer Billie S | Aloe vera ointment |
US5288500A (en) | 1987-03-13 | 1994-02-22 | Benzon Pharma A/S | Oral composition containing particles comprising an active substance |
FR2613936B1 (en) | 1987-04-17 | 1990-03-30 | Centre Nat Rech Scient | APPLICATION OF RESINS CONSTITUTED BY FUNCTIONAL POLYMERS AS A STATIONARY PHASE IN AFFINITY CHROMATOGRAPHY FOR THE PURIFICATION OF GROWTH FACTORS AND CORRESPONDING PURIFICATION METHOD |
US5690954A (en) | 1987-05-22 | 1997-11-25 | Danbiosyst Uk Limited | Enhanced uptake drug delivery system having microspheres containing an active drug and a bioavailability improving material |
DE3726797A1 (en) | 1987-08-12 | 1989-02-23 | Bayer Ag | MEDICINAL PRODUCTS FOR ORAL CAVES |
US5059189A (en) | 1987-09-08 | 1991-10-22 | E. R. Squibb & Sons, Inc. | Method of preparing adhesive dressings containing a pharmaceutically active ingredient |
EP0308181A1 (en) * | 1987-09-14 | 1989-03-22 | Novo Nordisk A/S | Trans-mucosal delivery formulations and a method for preparation thereof |
GB8723846D0 (en) | 1987-10-10 | 1987-11-11 | Danbiosyst Ltd | Bioadhesive microsphere drug delivery system |
DE3886880T2 (en) * | 1987-10-15 | 1994-07-14 | Syntex Inc | Powdery preparations for intranasal administration of polypeptides. |
US5246708A (en) | 1987-10-28 | 1993-09-21 | Pro-Neuron, Inc. | Methods for promoting wound healing with deoxyribonucleosides |
US5064650A (en) | 1988-04-19 | 1991-11-12 | Southwest Research Institute | Controlled-release salt sensitive capsule for oral use and adhesive system |
US5438076A (en) | 1988-05-03 | 1995-08-01 | Perio Products, Ltd. | Liquid polymer composition, and method of use |
US4925677A (en) | 1988-08-31 | 1990-05-15 | Theratech, Inc. | Biodegradable hydrogel matrices for the controlled release of pharmacologically active agents |
GB8826116D0 (en) * | 1988-11-08 | 1988-12-14 | Danbiosyst Ltd | Adhesive drug delivery composition |
GEP20022681B (en) | 1989-01-31 | 2002-04-25 | Aaronson Us Stuart A | Protein KFG, Antibodies, Pharmaceutical Composition, Their Use, recombinant DNA, Cell, Method for Discoveries and Production of Proteins, Method for Stimulation of Epithelial Cells Growth |
US5356630A (en) | 1989-02-22 | 1994-10-18 | Massachusetts Institute Of Technology | Delivery system for controlled release of bioactive factors |
US5576288A (en) | 1989-04-27 | 1996-11-19 | The Salk Institute For Biological Studies | Fibroblast growth factor conjugates |
US5191067A (en) | 1989-04-27 | 1993-03-02 | The Salk Institute For Biological Studies | Fibroblast growth factor conjugates |
US5130418A (en) | 1989-05-02 | 1992-07-14 | California Biotechnology Inc. | Method to stabilize basic fibroblast growth factor |
US5599551A (en) | 1989-06-06 | 1997-02-04 | Kelly; Patrick D. | Genital lubricants containing zinc as an anti-viral agent |
US5545673A (en) | 1989-06-06 | 1996-08-13 | Kelly; Patrick D. | Method for reducing risk of infection by sexually transmitted viruses |
US5208031A (en) | 1989-06-06 | 1993-05-04 | Kelly Patrick D | Sexual lubricants containing zinc as an anti-viral agent |
US5079018A (en) | 1989-08-14 | 1992-01-07 | Neophore Technologies, Inc. | Freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs |
US5158934A (en) | 1989-09-01 | 1992-10-27 | Genentech, Inc. | Method of inducing bone growth using TGF-β |
US5422340A (en) | 1989-09-01 | 1995-06-06 | Ammann; Arthur J. | TGF-βformulation for inducing bone growth |
JP2911496B2 (en) | 1989-09-11 | 1999-06-23 | 帝國製薬株式会社 | Highly absorbable vaginal agent containing bioactive polypeptide |
US5707644A (en) | 1989-11-04 | 1998-01-13 | Danbiosyst Uk Limited | Small particle compositions for intranasal drug delivery |
GB2237510B (en) * | 1989-11-04 | 1993-09-15 | Danbiosyst Uk | Small particle drug compositions for nasal administration |
US5512306A (en) | 1992-06-19 | 1996-04-30 | Pharmica Ab | Smoking substitute |
US5188825A (en) | 1989-12-28 | 1993-02-23 | Iles Martin C | Freeze-dried dosage forms and methods for preparing the same |
US5284659A (en) | 1990-03-30 | 1994-02-08 | Cherukuri Subraman R | Encapsulated flavor with bioadhesive character in pressed mints and confections |
US5217954A (en) | 1990-04-04 | 1993-06-08 | Scios Nova Inc. | Formulations for stabilizing fibroblast growth factor |
IL98087A (en) | 1990-05-04 | 1996-11-14 | Perio Prod Ltd | Colonic drug delivery system |
US5612211A (en) | 1990-06-08 | 1997-03-18 | New York University | Stimulation, production and culturing of hematopoietic progenitor cells by fibroblast growth factors |
SE9002339L (en) | 1990-07-04 | 1992-01-05 | Kabi Pharmacia Ab | THERAPEUTIC COMPOSITION AND PROCEDURE FOR ITS PREPARATION |
US5714458A (en) | 1990-07-18 | 1998-02-03 | Farmitalia Carlo Erba S.R.L. | Stable pharmaceutical compositions containing a fibroblast growth factor |
US5071644A (en) | 1990-08-07 | 1991-12-10 | Mediventures, Inc. | Topical drug delivery with thermo-irreversible gels |
KR930006431B1 (en) | 1990-10-11 | 1993-07-16 | 재단법인 한국화학연구소 | Microcapsulation of drugs |
DK0486862T3 (en) | 1990-11-23 | 1996-06-24 | American Cyanamid Co | Chimeric fibrolast growth factor |
US5215758A (en) | 1991-09-11 | 1993-06-01 | Euroceltique, S.A. | Controlled release matrix suppository for pharmaceuticals |
US5192802A (en) | 1991-09-25 | 1993-03-09 | Mcneil-Ppc, Inc. | Bioadhesive pharmaceutical carrier |
US5318780A (en) | 1991-10-30 | 1994-06-07 | Mediventures Inc. | Medical uses of in situ formed gels |
ATE140594T1 (en) | 1991-11-14 | 1996-08-15 | Gist Brocades Nv | METHOD FOR PRODUCING JUICES FROM FRUITS AND VEGETABLES |
US6033712A (en) * | 1994-05-13 | 2000-03-07 | Ei Du Pont De Nemours And Company | Gel production from plant matter |
US5266318A (en) | 1991-12-09 | 1993-11-30 | Royale Renaissance, Inc. | Skin therapeutic mixture containing cold-processsed aloe vera extract, with yellow sap and aloin removed |
EP0661966B1 (en) | 1991-12-17 | 2000-07-19 | Biovail Technologies Ltd. | Ulcer prevention and treatment composition and method |
DE4201172C1 (en) | 1992-01-17 | 1993-07-22 | Alfatec-Pharma Gmbh, 6900 Heidelberg, De | Pellets contg. Aloe vera extract - useful, e.g. as antiinflammatory of antibiotic agents, or for treating gastric ulcers |
US5578307A (en) | 1992-01-17 | 1996-11-26 | Alfatec-Pharma Gmbh | Shaped articles containing plant extract(s), in particular pellets, and their pharmaceutical or cosmetic use |
CA2108277A1 (en) | 1992-02-14 | 1993-08-15 | Mitsuru Watanuki | Preparation for the therapy of respiratory tract diseases |
US6197346B1 (en) * | 1992-04-24 | 2001-03-06 | Brown Universtiy Research Foundation | Bioadhesive microspheres and their use as drug delivery and imaging systems |
US6582728B1 (en) * | 1992-07-08 | 2003-06-24 | Inhale Therapeutic Systems, Inc. | Spray drying of macromolecules to produce inhaleable dry powders |
US5589451A (en) | 1992-09-21 | 1996-12-31 | Board Of Regents, The University Of Texas System | Methods and treaments for corneal healing with hepatocyte and keratinocyte growth factors |
US5703047A (en) | 1992-09-21 | 1997-12-30 | Board Of Regents, The University Of Texas System | Methods and treatments for corneal healing with growth factors |
US5645827A (en) | 1992-09-30 | 1997-07-08 | Union Carbide Chemicals & Plastics Technology Corporation | Muco-adhesive polymers |
JP3266674B2 (en) * | 1992-11-19 | 2002-03-18 | クミアイ化学工業株式会社 | Plant growth regulator composition |
GB9310412D0 (en) * | 1993-05-20 | 1993-07-07 | Danbiosyst Uk | Nasal nicotine system |
US5409703A (en) | 1993-06-24 | 1995-04-25 | Carrington Laboratories, Inc. | Dried hydrogel from hydrophilic-hygroscopic polymer |
US5453492A (en) | 1993-07-28 | 1995-09-26 | La Jolla Cancer Research Foundation | 60 kDa transforming growth factor-β-binding protein and its use to detect or purify TGF-β |
US5464815A (en) | 1993-09-08 | 1995-11-07 | Genentech, Inc. | Inhibition of heparin-binding |
US5435997A (en) | 1994-02-08 | 1995-07-25 | Burns; Michael J. | Topical agent and method for the treatment of pseudofolliculitis barbae |
DK0881908T3 (en) | 1994-03-08 | 2004-10-25 | Osteosa Inc | Use of fiber blast growth factors to stimulate bone growth |
US5656598A (en) | 1994-03-08 | 1997-08-12 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Use of fibroblast growth factors to stimulate bone growth |
US5503822A (en) | 1994-04-01 | 1996-04-02 | Schulman; Jerome M. | Medicated gel |
US5571531A (en) | 1994-05-18 | 1996-11-05 | Mcmaster University | Microparticle delivery system with a functionalized silicone bonded to the matrix |
GB9412394D0 (en) * | 1994-06-21 | 1994-08-10 | Danbiosyst Uk | Colonic drug delivery composition |
US5849327A (en) | 1994-07-29 | 1998-12-15 | Advanced Polymer Systems, Inc. | Delivery of drugs to the lower gastrointestinal tract |
JPH08198772A (en) * | 1994-11-25 | 1996-08-06 | Kirin Brewery Co Ltd | Powdery transnasal preparation containing granulocyte colony stimulation factor (g-csf) |
US5674495A (en) | 1995-02-27 | 1997-10-07 | Purdue Research Foundation | Alginate-based vaccine compositions |
AU695207B2 (en) * | 1995-03-28 | 1998-08-06 | Fidia Farmaceutici S.P.A. | Nanospheres comprising a biocompatible polysaccharide |
US5612053A (en) * | 1995-04-07 | 1997-03-18 | Edward Mendell Co., Inc. | Controlled release insufflation carrier for medicaments |
US5753622A (en) | 1995-05-10 | 1998-05-19 | University Technologies International, Inc. | Use of epidermal growth factor as a gastrointestinal therapeutic agent |
US5693775A (en) | 1995-05-12 | 1997-12-02 | The Johns Hopkins University School Of Medicine | Fibroblast growth factor homologous factor-1 (FHF-1) and methods of use |
JP3098401B2 (en) * | 1995-07-12 | 2000-10-16 | 株式会社エルティーティー研究所 | Formulation for nasal administration |
GB9514438D0 (en) * | 1995-07-14 | 1995-09-13 | Danisco | Stabilisation process and an enzyme for use in such a process |
US5900238A (en) * | 1995-07-27 | 1999-05-04 | Immunex Corporation | Vaccine delivery system |
US5902796A (en) * | 1995-09-22 | 1999-05-11 | Carrington Laboratories, Inc. | Bioactive factors of aloe vera plants |
US5656734A (en) | 1995-10-30 | 1997-08-12 | Systems Bio-Industries | Methods for making pectin and pectocellulosic products |
GB9525083D0 (en) * | 1995-12-07 | 1996-02-07 | Danbiosyst Uk | Vaccine compositions |
GB9600272D0 (en) * | 1996-01-06 | 1996-03-06 | Univ Nottingham | Polymers |
US5840332A (en) | 1996-01-18 | 1998-11-24 | Perio Products Ltd. | Gastrointestinal drug delivery system |
US6231888B1 (en) * | 1996-01-18 | 2001-05-15 | Perio Products Ltd. | Local delivery of non steroidal anti inflammatory drugs (NSAIDS) to the colon as a treatment for colonic polyps |
US5760102A (en) | 1996-02-20 | 1998-06-02 | Carrington Laboratories, Inc. | Uses of denture adhesive containing aloe extract |
ATE260646T1 (en) * | 1996-04-16 | 2004-03-15 | Novartis Consumer Health Sa | RAPID DISSOLVING ORAL DOSAGE FORM |
DK0928207T4 (en) * | 1996-07-10 | 2008-05-05 | Coloplast As | Adhesive and use of this agent |
GB9707934D0 (en) * | 1997-04-18 | 1997-06-04 | Danbiosyst Uk | Improved delivery of drugs to mucosal surfaces |
US6210710B1 (en) * | 1997-04-28 | 2001-04-03 | Hercules Incorporated | Sustained release polymer blend for pharmaceutical applications |
US6197327B1 (en) * | 1997-06-11 | 2001-03-06 | Umd, Inc. | Device and method for treatment of dysmenorrhea |
US6416779B1 (en) * | 1997-06-11 | 2002-07-09 | Umd, Inc. | Device and method for intravaginal or transvaginal treatment of fungal, bacterial, viral or parasitic infections |
US5874094A (en) * | 1997-08-05 | 1999-02-23 | Costello; Jeremiah | Cream formulation for topical application |
AR017512A1 (en) * | 1997-08-22 | 2001-09-12 | Smithkline Beecham Corp | TABLETS OF QUICKLY DISPOSABLE METILCELLULOSE FOR ORAL ROUTE ADMINISTRATION AND PROCEDURE TO PREPARE THEM |
NZ504108A (en) * | 1997-09-26 | 2002-06-28 | Noven Pharma | Bioadhesive compositions comprising a polyvinylpyrrolidone polymer and methods for topical administration of active agents |
JP4234803B2 (en) * | 1997-10-27 | 2009-03-04 | 久光製薬株式会社 | Pharmaceutical composition with controlled drug release rate |
GB9725084D0 (en) * | 1997-11-28 | 1998-01-28 | Medeva Europ Ltd | Vaccine compositions |
DK1035833T3 (en) * | 1997-12-02 | 2006-01-09 | Archimedes Dev Ltd | Composition for nasal administration |
US6383495B1 (en) * | 1997-12-08 | 2002-05-07 | Council Of Scientific & Industrial Research | Herbal formulation useful for treatment of skin disorders |
GB9726916D0 (en) * | 1997-12-19 | 1998-02-18 | Danbiosyst Uk | Nasal formulation |
US6290964B1 (en) * | 1998-03-06 | 2001-09-18 | Kathleen Shupe | Antimicrobial agents isolated from aloe vera |
US6423345B2 (en) * | 1998-04-30 | 2002-07-23 | Acusphere, Inc. | Matrices formed of polymer and hydrophobic compounds for use in drug delivery |
US6313103B1 (en) * | 1998-05-13 | 2001-11-06 | Carrington Laboratories, Inc. | Pectic substance as a growth factor stabilizer |
US5929051A (en) * | 1998-05-13 | 1999-07-27 | Carrington Laboratories, Inc. | Aloe pectins |
FR2778566B1 (en) * | 1998-05-15 | 2001-07-20 | Sep Tarral | PECTIC PREPARATIONS FOR USE AS MEDICINAL MEDIA |
US6033651A (en) * | 1998-06-10 | 2000-03-07 | Revlon Consumer Products Corporation | Gel cosmetic compositions |
KR20000011247A (en) * | 1998-07-23 | 2000-02-25 | 김윤 | Composition and pharmaceutical dosage form for colonic drug delivery using polysaccharides |
US6063915A (en) * | 1998-07-30 | 2000-05-16 | Hercules Incorporated | Carrageenan compositions and methods for their production |
US6080783A (en) * | 1998-09-01 | 2000-06-27 | Gum Tech International, Inc. | Method and composition for delivering zinc to the nasal membrane |
US6060078A (en) * | 1998-09-28 | 2000-05-09 | Sae Han Pharm Co., Ltd. | Chewable tablet and process for preparation thereof |
US6531152B1 (en) * | 1998-09-30 | 2003-03-11 | Dexcel Pharma Technologies Ltd. | Immediate release gastrointestinal drug delivery system |
GB9828861D0 (en) * | 1998-12-31 | 1999-02-17 | Danbiosyst Uk | Compositions |
US6552024B1 (en) * | 1999-01-21 | 2003-04-22 | Lavipharm Laboratories Inc. | Compositions and methods for mucosal delivery |
US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
DE60030418T2 (en) * | 1999-03-17 | 2007-08-30 | Coloplast A/S | PRESSURE-SENSITIVE ADHESIVE COMPOSITION |
US6375963B1 (en) * | 1999-06-16 | 2002-04-23 | Michael A. Repka | Bioadhesive hot-melt extruded film for topical and mucosal adhesion applications and drug delivery and process for preparation thereof |
GB9924797D0 (en) * | 1999-10-20 | 1999-12-22 | West Pharm Serv Drug Res Ltd | Compound |
ES2254164T3 (en) * | 1999-10-29 | 2006-06-16 | Nektar Therapeutics | DRY POWDER COMPOSITIONS WITH IMPROVED DISPERSABILITY. |
WO2003024427A1 (en) * | 1999-12-20 | 2003-03-27 | Temple University Of The Commonwealth System Of Higher Education | Tableted oral extended release dosage form |
DE60005469T3 (en) * | 1999-12-22 | 2007-08-09 | Dsm Ip Assets B.V. | Pharmaceutical composition containing ascorbic acid and pectin |
US7833549B2 (en) * | 2000-01-19 | 2010-11-16 | Mannkind Corporation | Dry powder formulations of antihistamine for nasal administration |
US6228387B1 (en) * | 2000-01-27 | 2001-05-08 | Murray Borod | Integrated comprehensive hemorrhoid treatment compositions and regimen |
JP4711520B2 (en) * | 2000-03-21 | 2011-06-29 | 日本ケミカルリサーチ株式会社 | Bioactive peptide-containing powder |
US6368639B1 (en) * | 2000-03-24 | 2002-04-09 | Council Of Scientific And Industrial Research | Herbal skin care formulation and a process for the preparation thereof |
US6248360B1 (en) * | 2000-06-21 | 2001-06-19 | International Health Management Associates, Inc. | Complexes to improve oral absorption of poorly absorbable antibiotics |
US6365200B1 (en) * | 2000-07-19 | 2002-04-02 | Jason C. Birnholz | Topical skin sensitizer |
EP1320387B1 (en) * | 2000-09-13 | 2012-04-11 | Praecis Pharmaceuticals Incorporated | Pharmaceutical compositions for sustained delivery of peptides |
US6596297B2 (en) * | 2000-10-30 | 2003-07-22 | New York Blood Center, Inc. | Biodegradable microbicidal vaginal barrier device |
US6777000B2 (en) * | 2001-02-28 | 2004-08-17 | Carrington Laboratories, Inc. | In-situ gel formation of pectin |
MXPA04001768A (en) * | 2001-09-03 | 2004-11-22 | Dsm Ip Assets Bv | Compositions comprising pectin and ascorbic acid. |
BR0214279A (en) * | 2001-11-19 | 2005-12-20 | Becton Dickinson Co | Pharmaceutical compositions in particulate form |
JP2004002320A (en) * | 2002-03-04 | 2004-01-08 | Medorekkusu:Kk | Liquid matrix causing in-vivo phase transition and liquid oral preparation |
-
2003
- 2003-08-29 US US10/652,622 patent/US7494669B2/en not_active Expired - Fee Related
-
2004
- 2004-05-24 CA CA2537290A patent/CA2537290C/en not_active Expired - Fee Related
- 2004-05-24 WO PCT/US2004/016146 patent/WO2005023176A2/en active Application Filing
- 2004-05-24 EP EP04753044A patent/EP1663111A4/en not_active Withdrawn
- 2004-05-24 JP JP2006524618A patent/JP4765020B2/en not_active Expired - Fee Related
- 2004-05-24 AU AU2004270101A patent/AU2004270101A1/en not_active Abandoned
- 2004-05-24 EA EA200600484A patent/EA010351B1/en not_active IP Right Cessation
- 2004-05-24 KR KR1020067004256A patent/KR20060127841A/en not_active Application Discontinuation
- 2004-05-24 CN CNA2004800248478A patent/CN1874679A/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4978528A (en) * | 1986-06-23 | 1990-12-18 | Bio Serae Laboratoires S.A. | Process for preventing degradation of an anti-bacterial composition |
Also Published As
Publication number | Publication date |
---|---|
CN1874679A (en) | 2006-12-06 |
WO2005023176A2 (en) | 2005-03-17 |
CA2537290C (en) | 2013-07-09 |
US7494669B2 (en) | 2009-02-24 |
JP4765020B2 (en) | 2011-09-07 |
JP2007504129A (en) | 2007-03-01 |
EA200600484A1 (en) | 2006-10-27 |
EP1663111A4 (en) | 2009-10-21 |
KR20060127841A (en) | 2006-12-13 |
US20050084534A1 (en) | 2005-04-21 |
AU2004270101A1 (en) | 2005-03-17 |
CA2537290A1 (en) | 2005-03-17 |
EP1663111A2 (en) | 2006-06-07 |
EA010351B1 (en) | 2008-08-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005023176A3 (en) | Delivery of physiologixal agents with in-situ gels comprising anionic polysaccharides | |
WO2002067897A3 (en) | In-situ gel formation of pectins | |
EP2322215A3 (en) | Combination treatment for non-hematologic malignancies using an anti-IGF-1R antibody | |
EP1790340A3 (en) | Combination chemotherapy | |
WO2005039499A3 (en) | Rapidly disintegrating film | |
EP2626368A3 (en) | Insulin-oligomer conjugates, formulations and uses thereof | |
WO2004071529A3 (en) | Uses of anti-insulin-like growth factor i receptor antibodies | |
IL192104A (en) | Formulation suitable for subcutaneous administration comprising ctla4ig molecules, sugar and a pharmaceutically acceptable aqueous carrier and use thereof for preparation of a medicament | |
WO2009102467A3 (en) | Devices, formulations, and methods for delivery of multiple beneficial agents | |
WO2002045684A3 (en) | Rapidly dispersing pharmaceutical composition comprising effervescent agents | |
WO2007079147A3 (en) | A delivery vehicle for probiotic bacteria comprising a dry matrix of polysaccharides, saccharides and polyols in a glass form and methods of making same | |
WO2009048945A8 (en) | Rapid mucosal gel or film insulin compositions | |
WO2004070017A3 (en) | Long-lasting, flavored dosage forms for sustained release of beneficial agents within the mouth | |
MY145790A (en) | Composition | |
EP3492069A3 (en) | Pharmaceutical compositions | |
MX2009003030A (en) | Galenic form for the trans-mucosal delivery of active ingredients. | |
EP2402003A3 (en) | Diclofenac formulations and methods of use | |
WO2006124681A3 (en) | Oral drug delivery system and methods of use thereof | |
WO2006121522A3 (en) | Implantable sensors and pumps, anti-scarring agents, and therapeutic compositions | |
WO2003047552A3 (en) | Pharmaceutical composition comprising a 5ht1 receptor agonist | |
WO2004066983A3 (en) | Controlled release of highly soluble agents | |
IL179177A (en) | Pharmaceutical composition comprising acyclovir and a delivery agent, a dosage unit, use of acyclovir in the preparation of the pharmaceutical composition, use of the pharmaceutical composition in the preparation of a medicament and a method of preparing the pharmaceutical composition | |
ATE454136T1 (en) | THERAPEUTIC COMPOSITIONS FOR PULMONARY ADMINISTRATION | |
WO2006050246A3 (en) | Formulations of water insoluble or poorly water soluble drugs in lipidated glycosaminoglycan particles, their manufacturing and their use for diagnostics and therapy | |
HK1120417A1 (en) | Stable nanoparticle formulations |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200480024847.8 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006524618 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2537290 Country of ref document: CA Ref document number: 1020067004256 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004270101 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2004270101 Country of ref document: AU Date of ref document: 20040524 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004753044 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1695/DELNP/2006 Country of ref document: IN Ref document number: 200600484 Country of ref document: EA |
|
WWP | Wipo information: published in national office |
Ref document number: 2004753044 Country of ref document: EP |